ATE507818T1 - Orale verabreichung eines calcitonins - Google Patents

Orale verabreichung eines calcitonins

Info

Publication number
ATE507818T1
ATE507818T1 AT08743617T AT08743617T ATE507818T1 AT E507818 T1 ATE507818 T1 AT E507818T1 AT 08743617 T AT08743617 T AT 08743617T AT 08743617 T AT08743617 T AT 08743617T AT E507818 T1 ATE507818 T1 AT E507818T1
Authority
AT
Austria
Prior art keywords
calcitonin
peptide drugs
oral administration
oral
bioavailability
Prior art date
Application number
AT08743617T
Other languages
English (en)
Inventor
Yatindra Joshi
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE507818T1 publication Critical patent/ATE507818T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
AT08743617T 2007-03-02 2008-02-29 Orale verabreichung eines calcitonins ATE507818T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89259407P 2007-03-02 2007-03-02
PCT/US2008/055399 WO2008109385A2 (en) 2007-03-02 2008-02-29 Oral administration of a calcitonin

Publications (1)

Publication Number Publication Date
ATE507818T1 true ATE507818T1 (de) 2011-05-15

Family

ID=39496395

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08743617T ATE507818T1 (de) 2007-03-02 2008-02-29 Orale verabreichung eines calcitonins

Country Status (16)

Country Link
US (1) US8410052B2 (de)
EP (1) EP2131810B1 (de)
JP (1) JP5249246B2 (de)
KR (2) KR20150091536A (de)
CN (2) CN107050433A (de)
AT (1) ATE507818T1 (de)
AU (1) AU2008223108B2 (de)
BR (1) BRPI0808517A2 (de)
CA (1) CA2679782C (de)
DE (1) DE602008006700D1 (de)
ES (1) ES2365648T3 (de)
MX (1) MX2009009243A (de)
PL (1) PL2131810T3 (de)
PT (1) PT2131810E (de)
RU (2) RU2009136303A (de)
WO (1) WO2008109385A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3326620B1 (de) 2010-12-16 2020-03-04 Novo Nordisk A/S Feste zusammensetzungen mit einem glp-1-agonisten und einem salz aus n-(8-(2-hydroxybenzoyl)amino)caprylsäure
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
BR112014006702A2 (pt) * 2011-09-22 2017-06-13 Exelixis Inc método para tratar osteoporose
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
EP4324475A1 (de) 2012-03-22 2024-02-21 Novo Nordisk A/S Zusammensetzungen von glp-1-peptiden und herstellung davon
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
AU2021259683A1 (en) * 2020-04-22 2022-11-17 Hadasit Medical Research Services & Development Limited Bioactive phenolate ionic complexes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
AU4218400A (en) 1999-04-05 2000-10-23 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
NZ531018A (en) 2001-08-17 2006-03-31 Novartis Ag 5-CNAC as oral delivery agent for parathyroid hormone fragments
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
PE20040724A1 (es) * 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
CA2532565C (en) * 2003-07-23 2012-05-08 Novartis Ag Use of calcitonin in osteoarthritis

Also Published As

Publication number Publication date
EP2131810A2 (de) 2009-12-16
KR20150091536A (ko) 2015-08-11
AU2008223108B2 (en) 2013-10-10
CA2679782A1 (en) 2008-09-12
KR20090116772A (ko) 2009-11-11
US8410052B2 (en) 2013-04-02
AU2008223108A1 (en) 2008-09-12
WO2008109385A2 (en) 2008-09-12
EP2131810B1 (de) 2011-05-04
RU2009136303A (ru) 2011-04-10
PL2131810T3 (pl) 2011-09-30
PT2131810E (pt) 2011-08-03
CN107050433A (zh) 2017-08-18
CA2679782C (en) 2015-02-17
US20100210526A1 (en) 2010-08-19
JP5249246B2 (ja) 2013-07-31
ES2365648T3 (es) 2011-10-07
CN101621991A (zh) 2010-01-06
KR101564114B1 (ko) 2015-10-28
MX2009009243A (es) 2009-09-08
WO2008109385A3 (en) 2009-04-09
BRPI0808517A2 (pt) 2014-08-19
RU2013150659A (ru) 2015-05-20
JP2010520221A (ja) 2010-06-10
AU2008223108A2 (en) 2009-09-10
DE602008006700D1 (de) 2011-06-16

Similar Documents

Publication Publication Date Title
ATE507818T1 (de) Orale verabreichung eines calcitonins
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
RS52367B (en) GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES
EA201070121A1 (ru) Лекарственная форма, содержащая слитый белок glp-1-fc
JP2009506076A5 (de)
EA200600877A1 (ru) Наночастицы для доставки лекарств
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
EA201100958A1 (ru) Фармацевтическая пероральная дозированная лекарственная форма на основе ингибиторов dpp iv
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
BR112013022044A2 (pt) veículo mastigável para absorção na boca
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
CO6260019A2 (es) Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento
MX2009002314A (es) Composiciones farmaceuticas que comprenden hgh para suministro oral.
DK1883387T3 (da) Beholder til flydende medikamenter, der skal administreres
WO2006026592A3 (en) Oral administration of poorly absorbed drugs, methods and compositions related thereto
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
MX2009011900A (es) Curacion de herida diabetica.
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BR112015000183A2 (pt) proteínas de superfície específicas de variante (vsp) de protozoário como carreadores para entrega de fármaco oral
BR112015014095A2 (pt) entrega transmucosal de acetato de glatirâmero
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2131810

Country of ref document: EP